U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C27H39ClN2O2
Molecular Weight 459.064
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AM-36

SMILES

CC(C)(C)C1=CC(CN2CCN(CC(O)C3=CC=C(Cl)C=C3)CC2)=CC(=C1O)C(C)(C)C

InChI

InChIKey=ZGSFWANJADAZQC-UHFFFAOYSA-N
InChI=1S/C27H39ClN2O2/c1-26(2,3)22-15-19(16-23(25(22)32)27(4,5)6)17-29-11-13-30(14-12-29)18-24(31)20-7-9-21(28)10-8-20/h7-10,15-16,24,31-32H,11-14,17-18H2,1-6H3

HIDE SMILES / InChI

Molecular Formula C27H39ClN2O2
Molecular Weight 459.064
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

AM-36 is a novel arylalkylpiperazine with combined antioxidant and Na(+) channel blocking actions. This compound was discovered as a four-year Amrad-funded program with the Departments of Pharmacology and Chemistry at Monash University. In preclinical studies was shown, that AM-36 might have great promise in the acute treatment of human stroke. But these investigation were discontinued.

CNS Activity

Curator's Comment: Known to be CNS penetrant in rats. Human data not available

Originator

Curator's Comment: AM36 was discovered as a four-year Amrad-funded program with the Departments of Pharmacology and Chemistry at Monash University

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Studies of synergy between morphine and a novel sodium channel blocker, CNSB002, in rat models of inflammatory and neuropathic pain.
2010 Jan

Sample Use Guides

in rats: nominal i.v. doses are: 0.2, 1 and 3 mg/kg
Route of Administration: Intravenous
AM-36 inhibited batrachotoxinin (BTX)-sensitive Na+ channel binding in rat brain homogenates with an IC50 of 0.28 uM. Veratridine (100 uM)-induced neurotoxicity in murine cerebellar granule cells was completely inhibited by AM-36 (1.7 uM) compared to only partial inhibition by sipatrigine (26 uM). Veratridine-stimulated glutamate release, as measured through a microdialysis probe in the cortex of anesthetised rats, was inhibited by 90% by superfusion of AM-36 (1000 uM).
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:35:17 GMT 2023
Edited
by admin
on Sat Dec 16 08:35:17 GMT 2023
Record UNII
08OBY024NY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AM-36
Common Name English
1-PIPERAZINEETHANOL, 4-((3,5-BIS(1,1-DIMETHYLETHYL)-4-HYDROXYPHENYL)METHYL)-.ALPHA.-(4-CHLOROPHENYL)-
Systematic Name English
Code System Code Type Description
PUBCHEM
9890390
Created by admin on Sat Dec 16 08:35:17 GMT 2023 , Edited by admin on Sat Dec 16 08:35:17 GMT 2023
PRIMARY
FDA UNII
08OBY024NY
Created by admin on Sat Dec 16 08:35:17 GMT 2023 , Edited by admin on Sat Dec 16 08:35:17 GMT 2023
PRIMARY
CAS
199467-52-2
Created by admin on Sat Dec 16 08:35:17 GMT 2023 , Edited by admin on Sat Dec 16 08:35:17 GMT 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY